Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
FORT LEE, NJ - Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company with a market capitalization of $225.5 million, announced Thursday it will not pursue further development of its NXP800 drug candidate for recurrent, platinum-resistant, ARID1a-mutated ovarian cancer, despite showing some clinical activity in a Phase 1b study. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt.
The study treated 17 patients with the target dose of 75 mg/day, with data available for 13 patients showing two partial responses and three stable diseases. Thrombocytopenia, identified as a key toxicity early in the study, was managed through an intermittent dosing schedule.
The company indicated it will evaluate potential development opportunities for NXP800 in other cancer types, including endometrial and prostate cancers, over the coming months.
Nuvectis also reported progress with its second clinical candidate, NXP900, which successfully completed both a drug-drug interaction study in healthy volunteers and a Phase 1a dose-escalation study in patients with advanced solid tumors. The company expects to initiate the Phase 1b program for NXP900 in the coming weeks.
"While the Phase 1b data provides evidence that NXP800 is biologically active in recurrent, platinum resistant, ARID1a-mutated ovarian cancer, we have decided to focus our near-term efforts on advancing NXP900," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis.
The Phase 1a study for NXP900 evaluated doses ranging from 20 to 300 mg/day, with no dose-limiting toxicity reached. The most common adverse events were primarily gastrointestinal-related and mild to moderate in intensity. The company reported robust inhibition of SRC kinase phosphorylation at doses of 150 mg/day and higher.
This information is based on a company press release statement. With analyst price targets ranging from $15 to $25, significantly above current trading levels, investors seeking deeper insights into Nuvectis’s financial health and growth prospects can access additional analysis through InvestingPro, which offers exclusive financial metrics and expert recommendations.
In other recent news, Nuvectis Pharma, Inc. has announced the completion of a drug-drug interaction study for its cancer drug candidate, NXP900. The study, conducted with 14 healthy volunteers, revealed that NXP900 acts as a weak inhibitor of the CYP3A enzyme. This classification indicates that NXP900 increased the concentration of midazolam, a CYP3A substrate, by less than two-fold. The findings support the potential use of NXP900 in combination with existing epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors. These developments are particularly relevant for the treatment of non-small cell lung cancer. The announcement reflects Nuvectis Pharma’s ongoing efforts in advancing its cancer treatment pipeline. This recent development could have implications for the company’s future strategies in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.